• [Epidemiology and clinical symptomatology of Creutzfeldt-Jakob disease].

      Mollenhauer, B; Zerr, I; Ruge, D; Krause, G; Mehnert, W H; Kretzschmar, H A; Poser, S; Helmholtz Centre for infection research, Inhoffenstr. 7, D-38124 Braunschweig, Germany. (2002-02-15)
      Analogous to prospective studies in other countries, prevalance and symptoms of sporadic Creutzfeldt-Jakob disease (CJD) were recorded in order to assess irregularities in the incidence of the disease in Germany since the onset of bovine spongioform encephalopathy (BSE).
    • Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

      Ultsch, Bernhard; Weidemann, Felix; Reinhold, Thomas; Siedler, Anette; Krause, Gerard; Wichmann, Ole; Helmholtz Centre for infection research, Inhoffenstr. 7, D-38124 Braunschweig, Germany. (2013)
      Herpes zoster (HZ) is a self-limiting painful skin rash affecting mostly individuals from 50 years of age. The main complication is postherpetic neuralgia (PHN), a long-lasting pain after rash has resolved. A HZ-vaccine has recently been licensed in Europe for individuals older than 50 years. To support an informed decision-making for a potential vaccination recommendation, we conducted a health economic evaluation to identify the most cost-effective vaccination strategy.
    • Herpes zoster in Germany: quantifying the burden of disease.

      Ultsch, Bernhard; Siedler, Anette; Rieck, Thorsten; Reinhold, Thomas; Krause, Gerard; Wichmann, Ole; Helmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany. (2011)
      Herpes zoster (HZ) is caused by a reactivation of the varicella-zoster-virus (VZV) and mainly affects individuals aged≥50 years. Vaccines have been licensed or are under development that can protect against HZ and its main complication postherpetic neuralgia (PHN). In Germany, the burden of disease caused by HZ is not well known. To support the decision making process related to a potential vaccination recommendation, we estimated annual HZ disease burden in people aged≥50 years in Germany by utilizing various data sources.
    • Update on the ongoing outbreak of haemolytic uraemic syndrome due to Shiga toxin-producing Escherichia coli (STEC) serotype O104, Germany, May 2011.

      Askar, M; Faber, M S; Frank, C; Bernard, H; Gilsdorf, A; Fruth, A; Prager, R; Hohle, M; Suess, T; Wadl, M; Krause, G; Stark, K; Werber, D; Helmholtz Centre for infection research, Inhoffenstr. 7, D-38124 Braunschweig, Germany. (2011)